Temsirolimus

Generic Name: Temsirolimus

Brand Names: Torisel

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₈₇NO_₁₆

CAS Number: 162635-04-3

Unique Ingredient Identifier: 624KN6GM2T

Background: Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication: For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions: Advanced Renal Cell Carcinoma

Associated Therapies: -

Clinical Trials

CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: B-cell Chronic Lymphocytic Leukemia
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Recurrent Marginal Zone Lymphoma
Malignant Neoplasm
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma

Interventions: Drug: temsirolimus

First Posted Date: 2006-02-13

Last Posted Date: 2014-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 89

Registration Number: NCT00290472

Locations: 🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States

and more 10 locations

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Stage IV Melanoma
Recurrent Melanoma

Interventions: Drug: sorafenib tosylate
Drug: temsirolimus
Drug: tipifarnib

First Posted Date: 2006-01-25

Last Posted Date: 2014-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 109

Registration Number: NCT00281957

Locations: 🇺🇸
Contra Costa Regional Medical Center, Martinez, California, United States
🇺🇸
El Camino Hospital, Mountain View, California, United States
🇺🇸
Great Falls Clinic, Great Falls, Montana, United States

and more 170 locations

Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function

Phase 1

Completed

Conditions: Hepatic Complications
Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: temsirolimus
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-01-11

Last Posted Date: 2013-01-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 130

Registration Number: NCT00275093

Locations: 🇺🇸
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States

Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: sorafenib tosylate
Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2005-11-21

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00255658

Locations: 🇺🇸
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States

An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients

Not Applicable

Completed

Conditions: Prostatic Neoplasms

First Posted Date: 2005-10-10

Last Posted Date: 2007-12-27

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 50

Registration Number: NCT00235794

Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck

Completed

Conditions: Squamous Cell Carcinoma

First Posted Date: 2005-09-19

Last Posted Date: 2007-12-27

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 20

Registration Number: NCT00195299

Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Recurrent Melanoma
Recurrent Renal Cell Cancer
Stage IV Melanoma
Stage IV Renal Cell Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: bryostatin 1
Drug: temsirolimus

First Posted Date: 2005-06-03

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00112476

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Adult Anaplastic Astrocytoma
Adult Anaplastic Oligodendroglioma
Adult Diffuse Astrocytoma
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Adult Pilocytic Astrocytoma
Adult Mixed Glioma
Adult Pineal Gland Astrocytoma
Adult Subependymal Giant Cell Astrocytoma

Interventions: Drug: erlotinib
Drug: temsirolimus
Other: pharmacological study
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2005-06-03

Last Posted Date: 2015-06-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 69

Registration Number: NCT00112736

Locations: 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
National Cancer Institute Neuro-Oncology Branch, Bethesda, Maryland, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 5 locations

CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Recurrent Mantle Cell Lymphoma

Interventions: Biological: rituximab
Drug: temsirolimus

First Posted Date: 2005-05-04

Last Posted Date: 2014-04-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 71

Registration Number: NCT00109967

Locations: 🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States
🇺🇸
Saint Mary Corwin Medical Center, Pueblo, Colorado, United States
🇺🇸
Graham Hospital Association, Canton, Illinois, United States

and more 190 locations

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Phase 1

Terminated

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Blastic Phase Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia
Relapsing Chronic Myelogenous Leukemia

Interventions: Drug: imatinib mesylate
Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2005-01-10

Last Posted Date: 2013-01-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00101088

Locations: 🇺🇸
University of California Medical Center At Irvine-Orange Campus, Orange, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy